Sorry about the confusion, yes skipping was the wrong phrase. Combining 2 and 3 or any way of fast tracking/decreasing the sample size would result it potential cost and time cuttings.
Yes, CUV has their SCENESSE product available in the EU and I believe Switzerland. Apparently US users are flying to Europe and pay for the treatment privately as FDA approval is still pending. I do not know how the process for the approval within the EU is working. Is there actually work being down by PAR to achieve that approval from the EU?
PAR -v- CUV, page-10
-
- There are more pages in this discussion • 119 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.015(7.32%) |
Mkt cap ! $76.98M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 22.5¢ | 21.0¢ | $242.2K | 1.102M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 16020 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.5¢ | 310000 | 2 |
View Market Depth
| Last trade - 16.10pm 04/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |